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Introduction {#sec005}
============

Colorectal and esophageal cancers are common malignant digestive diseases with high incidence and mortality worldwide \[[@pone.0158715.ref001]--[@pone.0158715.ref003]\]. Nearly one-half patients are diagnosed at an advanced stage, and there are still lack effective targeted therapies in colorectal and esophageal cancers, so survival rates in these cancers have not been improved markedly compared with hematopoietic and lymphoid malignancies. However, it is beneficial to monitor cancer progression for cancer patients \[[@pone.0158715.ref004]\].

Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) is an oncogene that is upregulated in various solid cancers \[[@pone.0158715.ref005], [@pone.0158715.ref006]\] and associated with poor prognosis, such as gastric cancer \[[@pone.0158715.ref007]--[@pone.0158715.ref009]\], hepatocellular cancer \[[@pone.0158715.ref010]\], lung cancer \[[@pone.0158715.ref011], [@pone.0158715.ref012]\] and \[[@pone.0158715.ref013]\] and etc. *LAPTM4B* exists as two allelic genes, which have the same sequence except for one 19 bp segment for *LAPTM4B \*1* and two tight tandem segments for *LAPTM4B \*2* in the 5' untranslated region of exon 1 \[[@pone.0158715.ref014]\]. Previous studies have demonstrated that *LAPTM4B \*2* allele was associated with significantly elevated risk of cancers, such as lung \[[@pone.0158715.ref015], [@pone.0158715.ref016]\], breast \[[@pone.0158715.ref017], [@pone.0158715.ref018]\], gastric \[[@pone.0158715.ref019]\], colon \[[@pone.0158715.ref020]\], ovarian \[[@pone.0158715.ref021]\], gallbladder cancer \[[@pone.0158715.ref022]\] and etc. Recent studies also suggested that *LAPTM4B \*2* was an independent prognostic biomarker for hepatocellular carcinoma \[[@pone.0158715.ref023]\], lung \[[@pone.0158715.ref024]\], breast \[[@pone.0158715.ref025]\], endometrial cancer patients \[[@pone.0158715.ref026]\] and etc.

According to our previous report, the *LAPTM4B\*2* allele frequency was 33.2% in colon cancer group, 25.5% in rectal cancer group, 22.7% in esophageal cancer group and 24.1% in health control group, indicating that *LAPTM4B\*2* was correlated with increased risk of colon cancer (*P* = 0.0016), but not with that of rectal and esophageal cancers \[[@pone.0158715.ref020]\]. However, there was no report about the association between the existence of two variant alleles of LAPTM4B with the prognosis in patients with colorectal and esophageal cancers. The present study aimed to investigate whether there is a correlation of *LAPTM4B* gene polymorphism with prognosis in colorectal and esophageal cancer patients after surgical resection.

Materials and Methods {#sec006}
=====================

Patients and Controls {#sec007}
---------------------

In this retrospective study, we collected 167 colon cancer cases (a discovery cohort including 72 patients from Department of Gastrointestinal Surgery between 1999 and 2006, and a testing cohort including 95 patients from Department of Clinical Laboratory between 1997 and 2006), 160 rectal cancer cases and 164 esophageal cancer cases who were hospitalized in Beijing Cancer Hospital, Peking University School of Oncology between June 1997 and December 2006. All patients underwent surgical resection and were finally confirmed according to the World Health Organization classification. The blood samples were stored in the biological tissue bank of Peking University Cancer Hospital & Institute. The tumor-node-metastasis (TNM) stage was determined according to the classification of the American Joint Committee on Cancer and International Union against Cancer. All patients who participated in our study underwent tumor resection at Clinical Oncology of Peking University with follow-up time of 1 to 209.2 months (median: 54.0 months) for colon cancer, 1--134.5 months (median: 60.0 months) for rectal cancer and 1--123.5 months (median: 37.5 months) for esophageal cancer. At the end of follow up, 56.9% (95/167), 55.3% (84/152) and 74.6% (97/130) patients died from colon, rectal and esophageal cancers, respectively.

This study had been approved by the Research and Ethical Committee of Peking University School of Oncology. Written informed consent was obtained from each patient participated in this study.

DNA extraction and PCR analysis {#sec008}
-------------------------------

Total genomic DNA was isolated from peripheral white cells using Blood Genomic DNA extraction kit following the manufacturer's instructions (Tiangen Beijing, China). DNA was dissolved in elution buffer, and its concentration was measured with a Nanodrop 2000 spectrophotomer (Thermo Fisher Scientific, Wilmington, Delaware, USA) and stored at -80°C until use.

Genotype of LAPTM4B was identified by PCR analysis using the primers 5'-GCCGACTAGGGGACTGGCGGA-3' (sense) and 5'-CGAGAGCTCCGAGCTTCTGCC-3' (antisense). PCR was carried out on a thermo cycler (Gene Cycler TM, Bio-Rad, CA, USA) in 20-μl volumes as follows: denaturation at 95°C for 5 min, followed by 35 cycles of 94°C for 30s, 65°C for 30s, 72°C for 30s. The last cycle was followed by auto-extension 72°C for 7 min with Taq DNA polymerase (Hotstar Taq plus, Qiagen, Valencia, California, USA). The amplified products were analyzed by electrophoresis in 10% polyacrylamide gel (visualized by gel-red).

Statistical analysis {#sec009}
--------------------

Statistical analysis was carried out by SPSS20.0 software (SPSS Inc., Chicago, IL). Chi-square test or Fisher's exact test was used to assess the correlation between the genotype and clinical parametric distributions in colorectal and esophageal cancer patients. The association of *LAPTM4B* gene polymorphism with overall survival (OS) was analyzed using Kaplan-Meier curves and log-rank test. Multivariate analysis determined the potential independent prognostic factors with Cox regression model. All tests of statistical significance were two-sided. *P* \< 0.05 was used as statistically significant level.

Results {#sec010}
=======

Genotypes of the *LAPTM4B* in colorectal and esophageal cancers {#sec011}
---------------------------------------------------------------

Three different genotypic *LAPTM4B* polymorphisms: *LAPTM4B\*1/1*, *LAPTM4B\*2/2* and *LAPTM4B\*1/2* were shown in [Fig 1A](#pone.0158715.g001){ref-type="fig"}. For *LAPTM4B\*1/1* and *LAPTM4B\*2/2*, we can observe fragments of 204-bp and 223-bp respectively. And both fragments can be observed in *LAPTM4B\*1/2* heterozygous individual.

![Genotypes of *LAPTM4B* distribution in colorectal and esophageal cancers.\
(A) Genotypes of *LAPTM4B* were separated in 10% polyacrylamide gel electrophoresis. Lanes 1, 2, 4, 8, 11: *LAPTM4B \*1/2*; lanes 3, 5, 6, 9, 10: *LAPTM4B \*1/1*; lanes 7: *LAPTM4B \*2/2*. (B) Distribution of genotypes of *LAPTM4B* in colorectal and esophageal cancers. *LAPTM4B* genotypes: \**1/1*, \**1/2* and \**2/2* frequencies were 44.6%, 42.3% and 13.1%, respectively, in colon cancer; 49.4%, 45.6% and 5.0%, respectively, in rectal cancer; 57.9%, 36.6% and 5.5%, respectively, in esophageal cancer. (C) Distribution of alleles of *LAPTM4B* in colorectal and esophageal cancers. LAPTM4B \*1 allele frequency was 65.8% in colon cancer; 72.2% in rectal cancer and 76.2% in esophageal cancer. And *LAPTM4B \*2* allele frequency was 34.2% in colon cancer; 27.8% in rectal cancer and 23.8% in esophageal cancer.](pone.0158715.g001){#pone.0158715.g001}

The genotypic and allele frequencies of *LAPTM4B* in colorectal and esophageal cancers were depicted in [Fig 1B](#pone.0158715.g001){ref-type="fig"}. Among 167 colon cancer cases, the *LAPTM4B* genotypes: \**1/1*, \**1/2* and \**2/2* frequencies were 44.6%, 42.3% and 13.1%, respectively. However, the genotype frequencies in 160 rectal cancer cases and 164 esophageal cancer cases were 49.4%, 45.6% and 5.0% vs. 57.9%, 36.6% and 5.5%, respectively ([Fig 1B](#pone.0158715.g001){ref-type="fig"}). In colon cancer cases, the *LAPTM4B \*2* allele frequency was 34.2%, which is different from that in rectal and esophageal cancer cases (27.8% and 23.8%, respectively) ([Fig 1C](#pone.0158715.g001){ref-type="fig"}).

Association between *LAPTM4B* genotypes and clinicopathological parameters in colorectal and esophageal cancers {#sec012}
---------------------------------------------------------------------------------------------------------------

The distribution of different genotypes of *LAPTM4B* was analyzed in clinicpathological parameters, including age, gender, lymph node metastasis, depth of invasion, distant metastasis, differentiation degree, gross type, TNM stage, location for colon cancer, CEA (carcinoembryonic antigen) for colorectal cancer and recurrence ([Table 1](#pone.0158715.t001){ref-type="table"}).The association of different genotypes of *LAPTM4B* with these clinical variables of colorectal and esophageal cancer patients did not reach statistical significance in our study. *LAPTM4B \*1/1* was more frequently detected in colon cancer patients with lymph node metastasis and TNM III+IV stages compared with non-lymph node metastasis and TNM I+II stages in total colon cancer (discovery + testing cohorts) (*P* = 0.106, 29.6% vs. 46.6% and *P* = 0.157 31.4% vs. 46.6%, respectively). *LAPTM4B \*2/2* decreased in recurrent patients compared with non-recurrent ones in total colon cancer patients (*P* = 0.045, 7.4% vs. 20.5%) ([Table 1](#pone.0158715.t001){ref-type="table"}) and in discovery and testing cohort (*P* = 0.203, 7.1% vs. 22.7% and *P* = 0.368, 7.6% vs. 17.2%, respectively) ([S1 Table](#pone.0158715.s001){ref-type="supplementary-material"}). However, *LAPTM4B\*1* was more frequently detected in colon cancer patients with moderate and well differentiation in colon discovery cohort (*P* = 0.011) ([S1 Table](#pone.0158715.s001){ref-type="supplementary-material"}). Such association was not found in colon testing cohort and total colon cancer cases.

10.1371/journal.pone.0158715.t001

###### Correlation of Distribution of various genotypes of *LAPTM4B* with clinicopathological parameters in colorectal and esophageal cancer patients.

![](pone.0158715.t001){#pone.0158715.t001g}

  Variables               Colon cancer   Rectal cancer        Esophagus cancer                                                
  ----------------------- -------------- --------------- ---- ------------------ ---- ---- --- ------- ---- ---- ---- ------- -------
  Age                                                                                                                         
  ≤60                     37             31              8    0.528              39   44   3   0.256        46   27   6       0.473
  \>60                    38             40              14                      40   29   5                49   33   3       
  Gender                                                                                                                      
  Male                    44             41              14   0.886              45   45   4   0.738        80   42   7       0.114
  Female                  30             30              8                       34   28   4                15   18   2       
  Lymph node metastasis                                                                                                       
  N0                      16             27              11   0.106              29   25   4   0.820        33   20   1       0.371
  N1+2                    34             31              8                       35   31   3                61   39   7       
  Undetermined            24             13              2                       15   17   1                1    1    1       
  Depth of invasion                                                                                                           
  T1+2                    5              5               3    0.691              15   11   1   0.815        26   17   1       0.579
  T3+4                    46             53              16                      52   47   6                70   42   7       
  Undetermined            23             13              2                       12   15   1                0    1    1       
  Distant metastasis                                                                                                          
  M0                      44             43              17   0.298              54   45   6   0.954        80   47   8       0.149
  M1                      14             20              3                       15   14   2                16   13   0       
  Undetermined            16             8               2                       10   14   0                0    0    1       
  Differentiation                                                                                                             
  Poor                    12             21              4    0.267              10   12   3   0.196        21   18   2       0.498
  Moderate+Well           52             49              17                      65   60   4                62   34   8       
  Undetermined            10             1               1                       4    1    1                13   8    1       
  Gross type                                                                                                                  
  Ulcerative type         31             34              11   0.673              40   40   4   0.152                          
  Protrude type           10             13              3                       8    2    1                                  
  Others                  3              8               3                       31   31   3                                  
  Undetermined            30             16              4                                                                    
  TNM stage                                                                                                                   
  I+II                    16             25              10   0.157              26   23   4   0.797        34   20   1       0.363
  III+IV                  41             37              10                      43   35   4                62   40   7       
  Undetermined            17             9               2                       10   15   0                0    0    1       
  Location                                                                                                                    
  Proximal                24             18              9    0.627                                                           
  Distal                  33             34              11                                                                   
  Undetermined            17             19              2                                                                    
  Recurrence                                                                                                                  
  No                      30             28              15   **0.045**          44   35   5   0.618   80   47   5    0.140   
  Yes                     44             43              7                       36   37   3           16   13   4            
  CEA                                                                                                                         
  Negative                33             31              7    0.984              40   26   3   0.365                          
  Positive                35             32              8                       32   32   5                                  
  Undetermined            6              8               7                       8    14   0                                  

Data was calculated by Chi-square test or Fisher's exact test.

CEA, carcinoembryonic antigen; *LAPTM4B*, lysosome-associated protein transmembrane 4 beta.

\*: Genotype.

Association of *LAPTM4B* genotypes with overall survival in colorectal and esophageal cancer patients {#sec013}
-----------------------------------------------------------------------------------------------------

Kaplan-Meier survival analysis and log-rank test indicated that colon cancer patients with *LAPTM4B \*1/1* genotype showed a shorter overall survival (OS) when compared with those with *LAPTM4B \*1/2* and *LAPTM4B \*2/2* genotypes (OS rate 33.8% vs. 43.7% and 72.7%, *P* = 0.0025) ([Fig 2A](#pone.0158715.g002){ref-type="fig"}). Moreover, patients with *LAPTM4B \*1* allele had a poorer prognosis than *LAPTM4B \*2* allele in total colon cancer cases (OS rate 33.8% vs. 50.5%, *P* = 0.0050) ([Fig 2B](#pone.0158715.g002){ref-type="fig"}). The same tendency of *LAPTM4B \*1/1* and *LAPTM4B \*1* was observed in the colon discovery and testing cohorts of colon cancer (*P* = 0.0417 and 0.0444, *P* = 0.0254 and 0.0292, respectively) ([Fig 2C--2F](#pone.0158715.g002){ref-type="fig"}). However, we did not find a marked relation between *LAPTM4B* genotypes or alleles and OS for rectal and esophageal cancer cases (*P* = 0.7418 and 0.8520 for various genotypes vs. *P* = 0.7669 and 0.9356 for different alleles, respectively) ([Fig 3A--3D](#pone.0158715.g003){ref-type="fig"}).

![Kaplan-Meier survival curves for survival comparison of colon cancer patients after surgery resection based on *LAPTM4B* genotypes and alleles.\
Overall survival (OS) after surgery resection based on: (A) *LAPTM4B* genotypes in total colon cancer (*P* = 0.025). (B) *LAPTM4B* alleles in total colon cancer (*P* = 0.0050). (C and D) *LAPTM4B* genotypes and alleles in colon discovery cohort (*P* = 0.0417 and 0.0254), respectively. (E and F) *LAPTM4B* genotypes and alleles in colon testing cohort (*P* = 0.0444 and 0.0292), respectively.](pone.0158715.g002){#pone.0158715.g002}

![Kaplan-Meier survival curves for survival comparison of rectal and esophageal cancer patients undergone surgery resection based on *LAPTM4B* genotypes and alleles.\
Overall survival (OS) after surgery resection based on: (A and B) *LAPTM4B* genotypes and alleles in rectal cancer (*P* = 0.7418 and 0.7669), respectively. (C and D) *LAPTM4B* genotypes and alleles in esophageal cancer (*P* = 0.8520 and 0.9356), respectively.](pone.0158715.g003){#pone.0158715.g003}

*LAPTM4B* genotype was an independent prognostic marker in patients with colon cancer, but not for rectal and esophageal cancer patients {#sec014}
----------------------------------------------------------------------------------------------------------------------------------------

The univariate Cox's model for OS of colorectal and esophageal cancer patients displayed that *LAPTM4B* genotype was one of the prognostic factors in total colon cancer patients (*P* = 0.006; HR: 0.565, 95% CI: 0.377--0.846), not in rectal and esophageal cancer patients (*P* = 0.692 and 0.958, respectively) ([Table 2](#pone.0158715.t002){ref-type="table"}).

10.1371/journal.pone.0158715.t002

###### Univariate analysis of the prognostic factors in colorectal and esophageal cancer patients by Log-rank test.

![](pone.0158715.t002){#pone.0158715.t002g}

  Variables                                                                                Colon cancer   Rectal cancer   Esophageal cancer                                                               
  ---------------------------------------------------------------------------------------- -------------- --------------- ------------------- ------- -------------- ------------- ------- -------------- -----------
  Age                                                                                                                                                                                                     
  ≤60                                                                                      1.468          0.969--2.222    0.070               1.069   0.702--1.628   0.757         1.415   0.948--2.112   0.090
  \>60                                                                                                                                                                                                    
  Gender                                                                                                                                                                                                  
  Male                                                                                     0.782          0.515--1.186    0.247               1.196   0.783--1.827   0.409         0.584   0.336--1.015   0.057
  Female                                                                                                                                                                                                  
  Lymph node metastasis                                                                                                                                                                                   
  N0                                                                                       4.385          2.375--8.096    **\<0.001**         1.838   1.115--3.031   **0.017**     1.628   1.041--2.548   **0.033**
  N1+2                                                                                                                                                                                                    
  Depth of invasion                                                                                                                                                                                       
  T1+2                                                                                     1.841          0.669--5.076    0.237               1.903   0.997--3.630   0.051         1.900   1.110--3.255   **0.019**
  T3+4                                                                                                                                                                                                    
  Distant metastasis                                                                                                                                                                                      
  M0                                                                                       6.687          4.134--10.815   **\<0.001**         4.990   3.012--8.266   **\<0.001**   2.306   1.390--3.825   **0.001**
  M1                                                                                                                                                                                                      
  Differentiation                                                                                                                                                                                         
  Poor                                                                                     1.116          0.679--1.836    0.665               0.779   0.438--1.384   0.394         1.348   0.825--2.201   0.233
  Moderate+Well                                                                                                                                                                                           
  Gross type                                                                                                                                                                                              
  Ulcerative type                                                                          1.035          0.717--1.496    0.853               0.427   0.133--1.374   0.154                                
  Protrude type                                                                                                                                                                                           
  Others                                                                                                                                                                                                  
  TNM stage                                                                                                                                                                                               
  I+II                                                                                     6.434          3.290--12.583   **\<0.001**         2.415   1.428--4.084   **0.001**     1.627   1.048--2.526   **0.030**
  III+IV                                                                                                                                                                                                  
  Location                                                                                                                                                                                                
  Proximal                                                                                 1.194          0.726--1.692    0.485                                                                           
  Distal                                                                                                                                                                                                  
  Recurrence                                                                                                                                                                                              
  No                                                                                       5.943          3.533--9.999    **\<0.001**         4.073   2.557--6.488   **\<0.001**   1.882   1.219--2.904   **0.004**
  Yes                                                                                                                                                                                                     
  CEA                                                                                                                                                                                                     
  Negative                                                                                 1.651          1.072--2.545    **0.023**           1.865   1.184--2.936   **0.007**                            
  Positive                                                                                                                                                                                                
  *LAPTM4B* genotype                                                                                                                                                                                      
  *[\*](#t002fn003){ref-type="table-fn"}1/1*                                               0.565          0.377--0.846    **0.006**           1.089   0.715--1.658   0.692         0.989   0.665--1.472   0.958
  *[\*](#t002fn003){ref-type="table-fn"}1/2*+ *[\*](#t002fn003){ref-type="table-fn"}2/2*                                                                                                                  

Data was calculated by Log-rank test. HR, hazard ratio; CI, confidence interval.

CEA, carcinoembryonic antigen; *LAPTM4B*, lysosome-associated protein transmembrane 4 beta.

\*: Genotype.

Furthermore, *LAPTM4B* genotype was a novel independent prognostic factor of OS for colon cancer (*P* = 0.004, HR = 0.432, 95% CI: 0.243--0.768), even in the colon discovery cohorts (*P* = 0.007, [S2 Table](#pone.0158715.s002){ref-type="supplementary-material"}), but not for rectal and esophageal cancer patients (*P* = 0.791, HR = 1.073, 95% CI: 0.638--1.804 vs. *P* = 0.998, HR = 1.000, 95% CI: 0.663--1.530, respectively). Depth of invasion, distant metastasis and recurrence were also independent prognostic factors for colon cancer (*P* = 0.014, *P*\<0.001 and *P*\<0.001, respectively). For rectal cancer patients, distant metastasis and recurrence were also independent prognostic factors (*P* = 0.021 and *P*\<0.001, respectively). In addition, distant metastasis (*P* = 0.025) was also an independent prognosis factor in esophageal cancer patients ([Table 3](#pone.0158715.t003){ref-type="table"}).

10.1371/journal.pone.0158715.t003

###### Multivariate analysis of the prognostic factors in colorectal and esophageal cancer patients by Cox proportional hazard regression model.

![](pone.0158715.t003){#pone.0158715.t003g}

  Variables                                                                                                                             Colon cancer   Rectal cancer   Esophageal cancer                                                               
  ------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------- ------------------- ------- -------------- ------------- ------- -------------- -------
  Age                                                                                                                                                                                                                                                  
  ≤60 vs \>60                                                                                                                           1.019          0.565--1.838    0.949               1.211   0.712--2.062   0.480         1.313   0.852--2.022   1.313
  Gender                                                                                                                                                                                                                                               
  Male vs Female                                                                                                                        0.864          0.498--1.500    0.603               1.225   0.705--2.129   0.471         0.765   0.408--1.434   0.765
  Depth of invasion                                                                                                                                                                                                                                    
  T1+2 vs T3+4                                                                                                                          4.240          1.275--14.102   **0.018**           1.494   0.689--3.242   0.309         1.528   0.848--2.751   0.158
  Lymph node metastasis                                                                                                                                                                                                                                
  N0 vs N1+3                                                                                                                            0.950          0.614--1.470    **0.819**           1.186   0.654--2.148   0.575         1.200   0.723--1.992   0.480
  Distant metastasis                                                                                                                                                                                                                                   
  M0 vs. M1                                                                                                                             4.517          2.281--8.945    **\<0.001**         2.173   1.122--4.208   **0.021**     1.988   1.089--3.629   0.025
  Recurrence                                                                                                                                                                                                                                           
  No vs. Yes                                                                                                                            6.898          3.061--15.543   **\<0.001**         3.748   1.896--7.411   **\<0.001**   1.577   0.980--2.537   0.061
  CEA                                                                                                                                                                                                                                                  
  Negative vs. Positive                                                                                                                 0.828          0.466--1.471    0.519               1.539   0.895--2.648   0.120                                
  *LAPTM4B* genotype                                                                                                                                                                                                                                   
  *[\*](#t003fn003){ref-type="table-fn"}1/1* vs *[\*](#t003fn003){ref-type="table-fn"}1/2*+*[\*](#t003fn003){ref-type="table-fn"}2/2*   0.432          0.243--0.768    **0.004**           1.073   0.638--1.804   0.791         1.000   0.663--1.530   0.998

Data was calculated by Cox regression test. HR, hazard ratio; CI, confidence interval.

CEA, carcinoembryonic antigen; *LAPTM4B*, lysosome-associated protein transmembrane 4 beta.

\*: Genotype.

Discussion {#sec015}
==========

Previous studies have demonstrated that LAPTM4B can play critical roles in various solid tumors, including proliferation, migration, invasion, apoptosis and angiogenesis \[[@pone.0158715.ref012], [@pone.0158715.ref027]--[@pone.0158715.ref029]\]. It also motivated multidrug resistance through promoting drug efflux by interacting with P-gp and activating PI3K/AKT signaling pathway \[[@pone.0158715.ref030]\]. In addition, new evidence has also revealed that LAPTM4B can participate in the autophagy initiation through binding with inactive epidermal growth factor receptor (EGFR) \[[@pone.0158715.ref031], [@pone.0158715.ref032]\].

In the present study, we revealed an independent prognostic role of *LAPTM4B* gene polymorphism in colon cancer patients who received surgical resection, but not in rectal and esophageal cancers. In our study, the *LAPTM4B \*2* allele frequency rate are 33.3%, 27.8% and 23.8%, nearly the same as previous report in colon, rectal and esophageal cancers \[[@pone.0158715.ref020]\], respectively. For the clinicopathological parameters, *LAPTM4B* genotype was correlated with recurrence in total colon cancer, especially for *LAPTM4B \*2/2* which decreased in recurrent colon cancer patients. There was not a relationship between *LAPTM4B* genotype and other clinical factors in colorectal and esophageal cancer patients. However, *LAPTM4B\*1* was more frequently detected in colon cancer patients with moderate and well differentiation in colon discovery cohort. This phenomenon might be caused by incomplete clinicopathological parameters in the present work. Furthermore, *LAPTM4B \*1/1* tended to be frequently detected in patients with lymph node metastasis and TNM III+IV stages in total colon cancer cases.

Patients with *LAPTM4B \*1* (genotypes \**1/1*) had a significantly poorer overall survival when compared with *LAPTM4B \*2* (genotypes \**1/2* or \**2/2*) patients in colon cancer (discovery and testing cohorts), but not in rectal and esophageal cancers. This is the first time demonstrating the *LAPTM4B \*1* allele as a poor prognostic indicator. The association of *LAPTM4B \*2* allele with colon cancer prognosis is not consistent with recent reports including in hepatocellular \[[@pone.0158715.ref023]\], ovary \[[@pone.0158715.ref027]\], lung \[[@pone.0158715.ref023]\], breast cancer \[[@pone.0158715.ref025]\] and etc. In hepatocellular carcinoma, Yang et al indicated that *LAPTM4B\*2* was correlated with tumor recurrence, poor histopathological differentiation and also an independent prognostic factor. Previous studies indicated that the 19-bp difference in 5' untranslated region of the first exon of the *LAPTM4B* gene can alter the ORF, resulting in two different protein isoforms: LAPTM4B-35 and -40 \[[@pone.0158715.ref014]\]. It might suggest that the 19-bp sequence plays an important role in transcriptional regulation or new isoform produced by *LAPTM4B\*2* may influence physiological activity and function of cancer cells.

Whereas in our study, *LAPTM4B \*1* allele shows a significant correlation with overall survival of colon cancer patients, but not in rectal and esophageal cancer patients. One explanation might be: the diverse expression patterns or isoforms of LAPTM4B in epithelial cells might demonstrate the difference of LAPTM4B genotype in prognosis in colon cancer vs rectal and esophageal cancers; the other explanation might be: the 19-bp sequence may play an important role in transcriptional regulation such as binding with the transcription factors or non-coding linker RNA in different cancers. Furthermore, in patients with gastric cancer, we have found that even though *LAPTM4B* genotype was correlated with susceptibility of gastric cancer, this polymorphism did not correlate with prognosis (data unpublished). The phenomenon illustrated the tumor heterogenicity between *LAPTM4B* genotype and its function, which discriminates with that in hepatocellular carcinoma, breast cancer and etc.

LAPTM4B was obviously up-regulated in various types of cancers \[[@pone.0158715.ref006]\]. Its overexpression might be caused by gene amplification and transcriptional up-regulation. However, the specific reason remains unknown. LAPTM4B has two different protein isoforms: LAPTM4B-24 (226 aa) and LAPTM4B-35 (317 aa). Li et al. has indicated that LAPTM4B-35 isoform can activate PI3K/Akt to participate multidrug resistance of cancer cells and anti-apoptosis \[[@pone.0158715.ref030]\]. Previous studies have proved that LAPTM4B-35 and -24 have different expression status and different roles in tissues and various cell lines of hepatocellular carcinoma \[[@pone.0158715.ref029], [@pone.0158715.ref033], [@pone.0158715.ref034]\]. Their balance may affect malignant transformation. However, a recent report has shown that LAPTM4B-24 isoform can stimulate mTORC1 via V-ATPase by influx of leu through binding with LAT1-4F2hc to lysosomes \[[@pone.0158715.ref035]\]. LAPTM4B-24 can also promote cell growth and proliferation \[[@pone.0158715.ref035]\].

As a result, the different LAPTM4B isoforms may play diverse functions in *LAPTM4B \*1* patients when compared with *LAPTM4B \*2* patients with colon cancer. Our findings on *LAPTM4B* alleles in colon cancer provide additional evidence that different *LAPTM4B* isoforms might play various roles, that is, LAPTM4B-35 can activate PI3K/Akt pathway and LAPTM4B -24 can activate mTORC1 pathway. Different isoform pattern might induce the function of 19 bp sequence in various cancers. Further studies should be carried out to elucidate this phenomenon. However, *LAPTM4B* genotype will be a useful biomarker for colon cancer patients when considering curative surgical resection.
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